Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment. However, how the treatment efficacy is related to 5-fluorouracil (5-FU) metabolic enzymes is unclear. We investigated genetic polymorphisms of the 5-FU metabolic enzymes in Japanese patients with HCC. We examined two genetic polymorphisms of the metabolic enzymes cytochrome P450 2A6 (CYP2A6) and dihydropyrimidine dehydrogenase (DPD) in 58 Japanese hepatitis C virus-seropositive HCC patients. To measure efficacy, we investigated genetic polymorphisms of the variable number of tandem repeats (VNTRs) of thymidylate synthase (TS) and classified the genotypes as high or low expression types. The frequency of the CYP2A6*4 allele (no-activity allele) among 58 HCC patients was 0.233 and a homozygous genotype (*4/*4) was found in five patients. The heterozygous genotype (T/C) of DPYD*9 (T85C) was detected in eight patients and the frequency of the DPYD*9 allele among 58 HCC patients was 0.069. Of 58 patients, 42 were classified as high expression type and 16 as low expression type for TS VNTR. Fifteen of these 16 patients appeared to have normal CYP2A6 metabolic activity and 13 of these 15 patients likely had normal DPD metabolic activity. Only 13 of 58 HCC patients (22.4%) tested may respond positively to treatment with oral tegafur/uracil. Therefore, when administering oral 5-FU in patients with HCC, it is important to consider three genetic polymorphisms (CYP2A6, DPYD, and TS) associated with 5-FU metabolic enzymes.
Introduction
Advanced hepatocellular carcinoma (HCC) with portal venous invasion, lymph node metastasis, and/or extrahepatic metastasis (such as bone or lung metastasis) has a very poor prognosis, and systemic and/or hepatic arterial infusion with chemotherapy is the main approach to treatment [1] [2] [3] [4] [5] [6] [7] . Many regimens of systemic and/or arterial infusion chemotherapy for such disease conditions have been reported, including intra-arterial cisplatin, intraarterial cisplatin/systemic interferon-a, systemic oral tegafur/uracil, systemic 5-fluorouracil (5-FU)/mitoxantrone/ cisplatin, systemic cisplatin/interferon-a-2b/doxorubicin/ FU, systemic doxorubicin/cisplatin/capecitabine, and intra-arterial 5-FU/systemic interferon-a [1] [2] [3] [4] [5] [6] [7] . Recently, sorafenib, an oral multikinase inhibitor with anti-angiogenic activity, was approved for the treatment of advanced HCC [8, 9] . Unfortunately, the median overall survival in patients with advanced HCC is less than 12 months, even if they receive treatment [1] [2] [3] [4] [5] [6] [7] [8] [9] . Because of the poor prognosis, maintenance of the patient's quality of life is an important consideration besides the efficacy of chemotherapy. Systemic oral tegafur/uracil therapy often causes fewer side effects than other treatments [1] [2] [3] [4] [5] [6] [7] [8] [9] . Therefore, oral tegafur/uracil is an essential agent for the treatment of advanced HCC. In such clinical settings, when oral tegafur/uracil therapy is started, the following three genetically predisposed factors should be considered: (a) whether oral tegafur/uracil is steadily bioactivated in the liver; (b) whether activated plasma 5-FU concentrations are adequate but not unacceptably toxic; and (c) whether the target enzyme of 5-FU in the patient is sensitive to the 5-FU administered.
First, an important factor is bioactivation of orally administered tegafur/uracil, which itself is a prodrug. Tegafur/uracil is absorbed from the gastrointestinal tract and is transported to the liver through the portal circulation [10] . It is then activated to 5-FU by the hepatic enzyme cytochrome P450 2A6 (CYP2A6) [11, 12] . In Japanese individuals, mutations that abolish or lower the enzyme activity of CYP2A6 such as CYP2A6*4 (deletion type) and CYP2A6*9 (-48T > G) with allele frequencies of 19.0-20.1% and 19.0-21.3%, respectively, have been reported [13] [14] [15] . In these individuals, orally administered tegafur/uracil may not be adequately bioactivated. 5-FU level has been found even after optimization of doses according to body surface area [16] . One factor that can generate such wide variations between patients may be genetic polymorphisms of the 5-FU metabolic enzyme dihydropyrimidine dehydrogenase (DPD), a primary and rate-limiting enzyme in pyrimidine base catabolism [17] [18] [19] [20] . As more than 80% of 5-FU administered is degraded to fluorinated b-alanine by DPD in vivo, the level of DPD catalytic activity affects the efficacy or the toxicity of 5-FU [16] [17] [18] [19] [20] . DPD deficiency has been reported to be associated with unacceptable toxicity to 5-FU-based chemotherapy in patients with cancer. Furthermore, homozygous carriers of DPYD, mutated alleles of DPD, show more severe toxic responses to 5-FU treatment than individuals with wild-type alleles, and an association between genetic polymorphisms of DPYD and DPD activity has been reported [17] [18] [19] [20] [21] [22] [23] [24] . Among Japanese individuals, mutations resulting in no or decreased DPD activity (DPYD*3, *9AB, *10, *11, and *12) should be checked before oral tegafur/uracil is administered, even though they are present in a very small percentage of the population [21] [22] [23] [24] .
The target enzyme for 5-FU is thymidylate synthase (TS). The TS gene (TYMS) is polymorphic, having either double (2R) or triple tandem (3R) repeats [variable number of tandem repeat (VNTR)] of a 28 base pair sequence in the promoter region [25] [26] [27] [28] [29] . TS expression predicts the response to 5-FU-based chemotherapy and its expression is determined by the TYMS promoter gene. Using additional functional single-nucleotide polymorphisms (SNPs) of the TYMS VNTR (G/C), Kawakami et al. [29] reported that TYMS genotypes could be classified into high and low expression types, which indicated the TS translation rate. They also showed that patients with colon cancer classified as low expression type had longer survival rates following 5-FU-based chemotherapy than patients not treated with 5-FU-based chemotherapy, and suggested that it is clinically important to examine polymorphisms of TYMS [29] .
How the efficacy of 5-FU-based chemotherapy for HCC is related to 5-FU metabolic enzymes is unclear. In the present study, we analyzed the genetic polymorphisms CYP2A6 and DPYD in HCC patients, and examined SNPs of TYMS VNTR and classified them as high and low expression types, with the aim of investigating the proportion of Japanese HCC patients who would potentially benefit from 5-FU-based chemotherapy.
Methods

Patients and DNA samples
Fifty-eight Japanese cirrhotic patients with HCC were studied. Cirrhosis and HCC were diagnosed by liver biopsy or computed tomography and ultrasonography. Patient characteristics are summarized in Table 1 . The use of patient blood samples for this study was approved by the Jikei University Ethics Committee. Peripheral blood was collected after obtaining written informed consent. These DNA samples were obtained from January 2005 to February 2009. The samples were numbered, unlinked, and tested anonymously. DNA was extracted from peripheral blood mononuclear cells using the standard protocol. DNA samples were also obtained from 44 Japanese healthy volunteers (aged 20-60 years) to determine the frequency of TSER (thymidylate synthase enhancer region) in control individuals. The volunteers were assessed to be physically normal on the basis of a comprehensive health examination.
Analysis of CYP2A6
CYP2A6*4 is a genetic polymorphism of CYP2A6 resulting in loss of function. PCR was performed to detect CYP2A6*4 using primers B4 and UTRAS1 [11] [12] [13] . The PCR reaction mixture contained 10 Â buffer, 2 mmol/l dNTPs, 10 pmol of each primer, 0.2 ml of Ampli Taq Gold, and 100 ng of genomic DNA. Amplification was performed by 35 cycles of denaturing at 941C for 1 min, annealing at 581C for 1 min, and extension at 721C for 1 min. After amplification of a 1.32 kb fragment, digestion was performed using two restriction enzymes: AccII and Eco81I. After overnight digestion at 371C, the samples were subjected to electrophoresis on a 2% TAE gel. The AccII-RFLP products of 1040 and 280 bp, and Eco81I-RFLP products of 728 and 428 bp were identified as the homozygous mutant allele of CYP2A6*4.
Genetic analysis of CYP2A6 [CYP2A6*4 (deletion) invader copy number assay]
We used the quantitative capability of the Invader system to determine gene copy number by comparing the target gene signal (CYP2A6) with that of a reference gene such as a-actin. The CYP2A6 probe set was designed to specifically react with the CYP2A6 sequence ( Table 2 ). The relative ratios of the CYP2A6 and reference gene signals from each assay allowed the identification and quantification of the deletion alleles of CYP2A6. Genomic DNA was extracted and Invader reactions were performed using 384-well plates with reagents containing Cleavase XI enzyme for genomic DNA, and both FAM and RED FRET cassettes. In brief, 3 ml of predenatured DNA samples (20 ng/ml) or no target control (10 ng/ml tRNA) were added to the appropriate wells, followed by the addition of 1.2 ml of signal probes/Invader oligo Mix, 1.4 ml of FRET Mix, and 0.4 ml of Cleavase/MgCl 2 solution for genomic DNA and an overlay of 6 ml of molecular biology-grade mineral oil. Following reagent dispensing, plates were spun for 10 s at 1000 rpm (120g), incubated at 631C for 3 h in a PTC-100 thermal cycler, and then directly read with a Cytofluor 4000 fluorescence plate reader (Applied Biosystems, Foster City, California, USA) using the settings given above [30] . For genotype determination, Fold Over Zero (FOZ) was used to confirm the validity of each sample assay [12] . The value was calculated using the program provided by Third Wave Technologies (Madison City, Wisconsin, USA). For the copy number assay, the NET FAM and RED FOZ values (for CYP2A6 and a-actin) were calculated and the ratio of the CYP2A6 to a-actin NET FOZ was calculated to identify the CYP2A6 copy number [30, 31] .
DPYD analysis
DPYD SNP analysis was carried out using the Invader system to determine gene copy number by comparing the target gene signals DPYD*3 (C189 deletion), *9 (T85C), *10 (G2983T), *11 (G1003T), and *12 (G62A) with that of the reference gene a-actin. Invader reactions were performed using the same conditions described above.
TS genotyping TS genotyping was performed by PCR for VNTR using a template of genomic DNA according to the methods described by Kawakami et al. [29] .The amplified DNA fragments were analyzed by electrophoresis on a 4% agarose gel, followed by staining with ethidium bromide. For heteroduplex analysis, PCR was performed using a primer labeled with fluorescein 5-isothiocyanate and analyzed by Spreadex gel (Elchrom Scientific, Cham, Switzerland). The PCR product from a sample of 2R/3R genotype forms a heteroduplex that appears on electrophoresis gels at a different position from the 3R band. The heteroduplex products showed three different electrophoresis patterns. PCR was performed using the forward primer TS25 5 0 -AGGCGCGCG GAAGGGGTCCT-3 0 and the reverse primer TS18 5 0 -TCCGAGCCGGCCACAGGCAT-3 0 . The PCR conditions were the same as those for TS VNTR. The PCR product was digested with HaeIII, followed by electrophoresis in 4% agarose gel and ethidium bromide staining. Analysis was carried out at least twice to confirm the genotype. According to the study by Kawakami et al. [29] , TS genotypes of 2R/3G, 3C/3G, and 3G/3G were considered high expression (H) types, whereas 2R/2R, 2R/3C, or 3C/ 3C were considered low expression (L) types.
Statistical analysis
The w 2 -test was used to compare the allele frequencies of all genotypes studied and frequencies of altered metabolic phenotypes between patients and healthy individuals. A P value less than 0.05 was considered statistically significant. 
Results
Genetic analysis of CYP2A6
The results of genetic analyses carried out in this study are summarized in 
DPYD analysis
Among 58 HCC patients, we did not find any SNP allele of *3 (C1897 deletion), *10 (G2983T), *11 (G1003T), or *12 (G62A), but detected a heterozygous mutation (T/C) of DPYD*9 (T85C) in eight patients. The frequency of the DPYD*9 allele in 58 HCC patients was 0.069. The homozygous mutation (C/C) of DPYD*9 was not found in 58 patients. 
Discussion
Oral tegafur/uracil therapy has often been used as a single agent to treat patients with HCC. Adjuvant therapy with oral tegafur/uracil for patients with advanced HCC is necessary to decrease the rate of recurrence, prolong the disease-free period, and maintain the quality of life for the patient. However, most physicians are not concerned whether the orally administered tegafur/uracil enters the systemic circulation and reaches the target site adequately and appropriately without increasing to a toxic concentration. Before initiating treatment with oral tegafur/uracil, at least two genetic polymorphisms should be checked: CYP2A6, by which tegafur is activated to 5-FU in the liver, and DPD, by which 5-FU is metabolized to the inactive form in the liver.
In Japanese individuals, CYP2A6*4 is the most frequent allele detected among the reported genetic polymorphisms that lead to loss of CYP2A6 metabolic activity [13] [14] [15] .
In the present study, the allele frequency of CYP2A6*4 was 0.233, which is not significantly different from that of 444 healthy Japanese individuals (0.184) reported by Ariyoshi et al. [32] . Five of 58 HCC patients were homozygous for CYP2A6*4, resulting in no enzyme activity, with a frequency of 0.086. This frequency was also not significantly different from that of healthy Japanese individuals (0.034).
A number of studies have reported considerable interindividual variability of plasma 5-FU levels [16, 33] . Although therapeutic drug monitoring (TDM) is an essential tool in such situations, an easy-to-use TDM for 5-FU is not yet available for clinical use. Therefore, physicians are required to take great care in avoiding unacceptable toxicity when treating patients with FU agents without TDM. Furthermore, the variability of plasma 5-FU levels is mainly because of the variability of DPD enzyme activity, and a linear relationship has been shown between DPD activity and 5-FU plasma clearance [34, 35] . The activity of DPD varies as a result of DPYD genetic polymorphisms [17] [18] [19] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . In the present study, we investigated five DPYD genetic polymorphisms in 58 HCC patients and found only one SNP of DPYD*9AB (T85C). The genotype frequency of the DYPD*9AB polymorphism in Japanese individuals has been reported previously, where the C-allele frequency was 3.7-6.3% [21] [22] [23] [24] , which is similar to the frequency (8 of 116 alleles, 6.9%) in the 58 HCC patients analyzed here. A study of 300 Taiwanese individuals reported a C-allele frequency of 4.3% and no CC homozygous genotype [36] . We also detected no CC genotype in the present study. However, a German study of 157 Caucasians found a higher frequency of 19.4% [37, 38] , indicating that the DPYD 85 C allele is more frequently observed in Caucasians than in Asians.
The DYPD*9AB (T85C) polymorphism, in which cysteine without electron polarity at the 29th amino acid is substituted by arginine with electron polarity, might result in a difference in enzyme activity. Gene expression experiments using Escherichia coli showed that the enzyme activity of DPD encoded by the 85 C allele was too low to be detected [23] . In a study of the TC heterozygous genotype in patients with cancer, DPD activity measured by high-performance liquid chromatography was more than 30% lower than that of normal individuals [23] . However, it remains controversial whether all individuals with a TC genotype have markedly low DPD activity in vivo.
In the setting of treating patients with cancer with FU, besides plasma levels of 5-FU, physicians should also consider whether 5-FU ultimately functions as an anticancer drug in individual cancer patients. The target enzyme for 5-FU is TS and the levels of TS expression in target tumors possibly determine the sensitivity to 5-FU as a TS inhibitor. TS mRNA is known to have a unique tandem repeat sequence in the 5 0 UTR and is polymorphic in terms of the number of these repeats (VNTRs) [25] [26] [27] [28] . The repeat length controls TS protein expression. Furthermore, Kawakami et al. [29] reported an additional polymorphism in VNTR of the TS gene as SNP, G/C polymorphism in TS VNTR, which is also a genetic variation that can potentially predict the effectiveness of 5-FU [29] . It was also reported that TS VNTR is related to TS protein expression by affecting the translational activity of TS mRNA and TS alleles show a frequent loss of heterozygosity. In the analysis of TS VNTR, in which a heteroduplex formed between 2R-derived and 3R-derived PCR products was separated by high-resolution gel, they observed different electrophoresis patterns of the heteroduplex. They confirmed the presence of a G/C polymorphic change (SNP) and classified the polymorphic allele as *2G, *2C, *3G, and *3C in accordance with the combination of the SNP and VNTR [29] . Functional analysis showed that the plasmid construct with the 3G sequence had three to four times greater efficiency of translation than the other polymorphic sequences. The TS genotype was analyzed according to the combination of the novel SNP and VNTR in patients with resected colorectal cancer (64 patients treated with four different oral 5-FU derivatives as adjuvant therapy and 47 patients with no adjuvant treatment). The genotypes were classified into a high expression type (*2/*3G, *3C/*3G and *3G/*3G) and a low expression type (*2/*2, *2/*3C and *3C/*3C). This new genotype classification was used to predict survival of the 111 patients. For the low expression type, patients who received oral fluoropyrimidine survived longer than the patients with no treatment. For the high expression type, however, no benefit of oral fluoropyrimidine was observed [29] .
Using the classification proposed by Kawakami and colleagues, we analyzed two polymorphisms of TS VNTR and classified the genotypes into high or low expression type in 58 HCC patients. Only 16 of 58 HCC patients had the low expression type, and could thus respond to 5-FU treatment. Whether the proposed classification of high or low expression type is appropriate to predict 5-FU anticancer efficacy is still being debated. Many subsequent studies have supported this classification [39] [40] [41] [42] , although others have not [43, 44] . Even though this issue remains controversial, TS genotyping may be a reliable tool to predict 5-FU clinical efficacy.
For a physician who faces the decision of initiating oral tegafur/uracil chemotherapy in a patient with cancer, it is essential to consider whether this drug will reach the cancer cells at a therapeutic concentration and would thus be effective in eliminating the cells. In the present study, we examined three potential genetic barriers (CYP2A6, DPYD, and TS) in 58 HCC patients, and 16 HCC patients (No. 1-No. 16 in Table 2 ) were classified as low TS expression type who would possibly respond to 5-FU treatment. Fifteen (No. 1-No. 15 in Table 2 ) of these 16 patients appeared to have normal CYP2A6 metabolic activity, and 13 (No. 3-No. 15 in Table 2 ) of these 15 patients probably had normal DPD metabolic activity. Hypothetically, only 13 of 58 HCC patients (22.4%) treated optimally with 5-FU are likely to have a favorable therapeutic outcome. The current study showed an important role for three genetic polymorphisms (CYP2A6, DPYD, and TS) of 5-FU metabolic enzymes in 5-FU-based chemotherapy in patients with HCC. Therefore, when administering oral 5-FU in patients with HCC, it is important to consider the genetic polymorphisms of the metabolic enzymes and provide tailor-made treatment in each case.
